Published Research

Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing

Kleinstiver BP*, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK*.  [*co-corresponding authors]

> Nature Biotechnology 2019

Discovery of widespread type I and type V CRISPR-Cas inhibitors

Marino ND, Zhang JY, Borges AL, Sousa AA, Leon LM, Rauch BJ, Walton RT, Berry JD, Joung JK, Kleinstiver BP, Bondy-Denomy J

> Science 2018

Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors

Tak YE, Kleinstiver BP, Nuñez JK, Hsu JY, Horng JE, Gong J, Weissman JS, Joung JK

> Nature Methods 2017

Enhanced proofreading governs CRISPR-Cas9 targeting accuracy

Chen JS*, Dagdas YS*, Kleinstiver BP*, Welch MM, Sousa AA, Harrington LB, Sternberg SH, Joung JK, Yildiz A, Doudna JA.   [* co-first authors]

> Nature 2017

Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells

Kleinstiver BP*, Tsai SQ*, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw ZR, Aryee MJ, Joung JK.   [* co-first authors]

> Nature Biotechnology 2016

High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects

Kleinstiver BP*, Pattanayak V*, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK.  [* co-first authors]

> Nature 2016

Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition

Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z, Joung JK

> Nature Biotechnology 2015

Engineered CRISPR-Cas9 nucleases with altered PAM specificities

Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JR, Aryee MJ, Joung JK.

> Nature 2015